EFFECTS OF DICLOFENAC AND L-745,337/ NS-398/ DFU, SELECTIVE CYCLOOXYGENASE-2- INHIBITORS, ON PROSTAGLANDIN- AND LEUKOTRIENE RELEASE IN BURSA SUBACROMIALIS TISSUE

*+Wittenberg, R. H., **Knorth, H., **Willburger, R. E., ***Theile, A., ****Plafki, C., *****Chantrain, M., ****Peskar, B. M., *+university clinic St. Josef-Hospital, dept. of orthopaedics, Gudrunstr. 56, 44791 Bochum, Germany, (0049)-0234-509-2530, (0049)-0234-509-2532 (fax), ralf.wittenberg@ruhr-uni-bochum.de

Introduction:

It is generally known, that prostaglandins (PG) and leukotrienes (LT) are strong mediators of inflammation. Local concentrations of PG and LT are found to be elevated in inflamed tissues. PG are synthesized by the two cyclooxygenase (cox) iso-enyzmes cox-1 and -2-. While cox-1 is constitutively expressed in almost any tissue and PG, generated via the cox-1 pathway play an essential role in physiological homoeostasis, little or no cox-2 is found in resting cells or tissues.

In contrast to cox-1, cox-2 gene expression is dramatically induced by cytokines or mitogens in inflammatory tissues and -cells. Likewise, PG synthesized via the cox-2 pathway support inflammation and contribute to clinical symptoms like oedema, redness, swelling and pain (Vane, Botting 1995).

Material and methods:

We compared the effects of both, classical, non-steroidal antiinflammatory drugs (NSAID), like diclofenac, and selective cox-2-inhibitors,

like L-745,337, NS-398 and DFU, on release of PGE₂, 6-keto-PGF1 $_{\alpha}$ and LTC₄ in inflamed bursa subacromialis tissue. Tissue was obtained from patients, suffering from impingement syndrome and taken by open surgery (n= 43).

At the time of operation, patients were at least 2 weeks without NSAID therapy and least 4 weeks without glucocorticoid therapy. Bursal specimens, 150-200 mg wet weight (w.w.) were incubated in modified tyrode solution at presence of graded concentrations of diclofenac,

L-745,337, NS-398 and DFU (0,1-1000 μ M).Each single specimen was analyzed histologically. Levels of PGE₂, 6-keto-PGF1 α and LTC₄ were measured by means of radioimmunoassay and formation of LTC₄ was stimulated using Calcium Ionophore A 23187 (5 mg/ 1 ml DMSO). Statistical analyses were performed using student's test for matched pair data.

Results:

Inflamed bursal tissue basic release (n=16) was 7,46 \pm 1,7 ng PGE2/ g w.w., 20,24 \pm 3,08 ng 6-keto-PGF1α/ g w.w. and 33,1 \pm 7,8 ng $\,$ LTC4/ g w.w.. Administration of 10 μM diclofenac decreased the release of PGE2 to

5,5 \pm 1,1 ng/ g w.w., of 6-keto-PGF1 $_\alpha$ to 11,4 \pm 2,32 ng/ g w.w. and increased release of LTC4 to 37,08 \pm 8,5 ng/ g w.w. respectively.

This equals 15 \pm 9,07 % (p< 0,05), 42,23 \pm 6,6 % (p< 0,001) inhibition and 24,88 \pm 11,42 % stimulation respectively.

Administration of 0,1/ 1/ 10/ 100/ 1000 μM diclofenac (n=7) caused the following inhibition of release:

 PGE_2 : 9,47 ± 29,69 %/ 50,07 ± 20,21 %/ 66,73 ± 5,78 %/

 $46,29 \pm 23,61 \% / 72,94 \pm 11,4 \%$. IC₅₀ value is $2,63 * 10^{-6}$ M.

6-keto-PGF1 $_{\alpha}$: 23,09 \pm 25,39 %/ 43 \pm 21,281 % (p< 0,05)/

 $54,52\pm16,6$ % (p< 0,05)/ 67,45 $\pm13,35$ % (p< 0,05)/ $53,38\pm34,02$ % . IC $_{50}$ value is $5.09*10^{-6}$ M.

Administration of 10/ 100/ 1000 μM L-745,337 (n=7) caused the following inhibition of release:

PGE₂: 15,47 \pm 18,46 %/ 51,9 \pm 8,86 % (p< 0,025)/

 $69.7 \pm 4.49 \%$ (p< 0.005). IC₅₀ value is $1.7 * 10^{-4}$ M. 6-keto-PGF1_{cc} -4.54 ± 20.24 %/ $67.45 \pm 13.35 \%$ (p< 0.01)/

 $6 - \text{Keto-FGF}_{00} = 4,34 \pm 20,24 \% \text{ of } 4,43 \pm 13,33 \% \text{ (p< 0,0)}$ $54,36 \pm 24,03 \% \text{ (p< 0,05)}$. IC₅₀ value is 2,36 * 10⁴ M.

LTC₄: $-16,22 \pm 20,15 \% / 16,39 \pm 11,85 \% / 32,32 \pm 14,75 \%$.

Administration of 10/ 100/ 1000 μM NS-398 (n=7) caused the following inhibition of release:

 PGE_2 : -69,78 \pm 61,64 %/ 26,74 \pm 15,3 %/ 84,36 \pm 6,89 % (p< 0,025).

 IC_{50} value is 2,95 *.10⁻⁴ M.

6-keto-PGF1_{α}: 13,33 ± 17,92 %/57 ± 6,77 % (p< 0,01)/

 $65,88 \pm 7,57 \%$ (p< 0,025). IC₅₀ value is $1,49 * 10^{-4}$ M.

LTC₄: $-42,09 \pm 24,71 \% / -7,1 \pm 20,23 \% / -21,46 \pm 20,38 \%$.

Administration of 1/ 10/ 100 μM DFU (n=3) caused the following inhibition of release:

 PGE_2 : -67,83 ± 89,5 %/ -27,46 ± 28,3 %/ 23,74 ± 26,66 %.

6-keto-PGF1_{α}: -36,15 ± 31,07 %/ -34,87 ± 45,78 %/ 2,84 ± 58,59 %.

Discussion:

Concentrations of all agents in the range of μM inhibit PG formation in bursal tissue. However, L-745,337, NS-398 and DFU inhibit PG formation in bursal tissue only at high concentrations ($\geq 100~\mu M$) that also inhibit cox-1 activity (Panara et al. 1995). At concentrations of L-745,337, NS-398 and DFU, that are selective for inhibition of cox-2 ($< 10~\mu M$) no significant inhibition on PG release can be detected. The data strongly suggest that the bulk of PG, generated in bursal tissue, is derived from the cox-1 pathway and that in therapy of the impingement syndrome, administration of cox-2 selective NSAID might be of little value.

Both, in acute and chronic cases of the impingement syndrome,

6-keto-PGF1 $_{\alpha}$, which is exclusively synthesized by endothelial cells, is released in high levels. A possible explanation could be the sizeable angiogenesis within granulating and chronically granulating bursal tissue respectively, revealed in the corresponding histologies.

Furthermore, levels of PG and LT seem to correspond directly to the extent of damage in the subacromial space and within the rotator cuff. Apparently, bursal tissue also performs mechanical tasks, especially if the rotator cuff is ruptured.

**university clinic St. Josef-Hospital, dept. of orthopaedics, Gudrunstr. 56, 44791 Bochum, Germany

***university clinic Bergmannsheil, dept. of histology,

Buerkle-de-la-Camp-Platz 1, 44789 Bochum, Germany

****Druckkammerzentrum am Marienkrankenhaus, Parade 3,

23552 Luebeck, Germany

*****ruhr-university of bochum, dep. of experimental, clinical medicine, Universitätsstr. 150, 44780 Bochum, Germany

References:

Vane, J. R., Botting, R. M., New insights into the mode of action of antiinflammatory drugs. Inflammation Res. 44: 1-10 (1995)

Panara, M. R., Greco A., Santini G. et al., Effects of novel antiinflammatory compounds NS-398 and L-745,337 on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. Br. J. Pharmacol. 116: 2429-434 (1995)

Acknowledgment:

Supported by a grant from the German Research Foundation (Deutsche Forschungs-Gesellschaft)

One or more of the authors have received something of value from a commercial or other party related directly or indirectly to the subject of my presentation.